John Libbey Eurotext

European Journal of Dermatology

Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab Volume 27, numéro 5, September-October 2017

Illustrations

  • Figure 1
Auteurs
1 Department of Dermatology,
Centro Hospitalar do Porto,
Portugal
2 Immunogenetics laboratory,
Instituto Ciências Biomédicas Abel Salazar,
University of Porto,
Portugal
3 Clínica Laser de Belém,
Lisboa,
Portugal
4 Instituto de Ciências Biomédicas Abel Salazar,
University of Porto,
Portugal
5 Dermatology Research Unit,
Centro Hospitalar do Porto,
Portugal

Psoriasis is a chronic inflammatory disease which is influenced by multiple genetic factors. Current knowledge supports that the same genetic features may influence clinical responsiveness to different therapies [1]. HLACw*0602 polymorphism is the main susceptibility gene in psoriasis and its expression is generally linked to an early onset, longer duration, and severity of the disease [2]. Other genetic risk factors have been identified, namely the IL-23R and IL-12β polymorphisms that are involved [...]